Pexidartinib for advanced tenosynovial giant cell tumor: results of the randomized phase 3 ENLIVEN study

BACKGROUND: Tenosynovial giant cell tumor (TGCT), a rare, locally aggressive neoplasm, overexpresses colony-stimulating factor 1 (CSF1). Surgery is standard with no approved systemic therapy. This phase 3 randomized, double-blind study evaluated pexidartinib, a CSF1 receptor inhibitor, in patients w...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Lancet
Egile Nagusiak: Tap, William D., Gelderblom, Hans, Palmerini, Emanuela, Desai, Jayesh, Bauer, Sebastian, Blay, Jean-Yves, Alcindor, Thierry, Ganjoo, Kristen, Martín-Broto, Javier, Ryan, Christopher W., Thomas, David M., Peterfy, Charles, Healey, John H., van de Sande, Michiel, Gelhorn, Heather L., Shuster, Dale E., Wang, Qiang, Yver, Antoine, Hsu, Henry H., Lin, Paul S., Tong-Starksen, Sandra, Stacchiotti, Silvia, Wagner, Andrew J.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2019
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6860022/
https://ncbi.nlm.nih.gov/pubmed/31229240
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0140-6736(19)30764-0
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak